A large number of clinical trials are underway to assess the therapeutic potential of mesenchymal
stromal cells. This is based on preclinical observations that point to the probable efficacy of these
cells. Very little is known however about the homing mechanisms of these cells to sites of injury and
inflammation. This is important if one is to enhance this process to improve the therapeutic
outcome. We have addressed this issue by highlighting what is known and through an analogy with
leukocyte homing, and have identified possible areas of future research.